1
|
Rathebe PC. Occupational exposure to silicon dioxide and prevalence of chronic respiratory symptoms in the cement manufacturing industries: A review. J Public Health Res 2023; 12:22799036231204316. [PMID: 37822998 PMCID: PMC10563475 DOI: 10.1177/22799036231204316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Accepted: 08/22/2023] [Indexed: 10/13/2023] Open
Abstract
The aim of this review was to assess the association between occupational exposure to silicon dioxide and chronic respiratory symptoms among workers in the cement manufacturing industries. Approximately 60 articles published from 2010 to 2021 were found and four independent reviewers extracted the data from each eligible study using PubMed, Google scholar etc. The following terms were used: exposure to cement dust, exposure to silicon dioxide etc. Inclusion and exclusion criteria were considered while searching for the studies. In this review, a total of 14 articles were included in this study. Chronic cough was the most prevalence exposure symptoms (OR 1.90; CI 9.90, 0.78), with wheezing reported to be the least experienced symptom (OR 1.34; CI 11.5, 0.50). Two studies reported exposure concentration ranging from 0.026 to 0.044 mg/m3, and 0.27 mg/m3 was also reported in one study. The FEV1 and FVC was lower in exposed workers when compared to the control group. Studies reported the crystalline silica quartz to be 21.5% in limestone, 22.5% in bauxite, 21.22% in clinker, and 21.22% in raw cement. Chronic cough, phlegm, wheezing, and shortness of breath or dyspnea was found to be significantly prevalence among workers, particularly cleaning personnel, in the cement manufacturing industries.
Collapse
Affiliation(s)
- Phoka C Rathebe
- Department of Environmental Health, Faculty of Health Sciences, University of Johannesburg, Johannesburg, South Africa
| |
Collapse
|
2
|
Nakamura J, Tsujino I, Yamamoto G, Nakaya T, Takahashi K, Kimura H, Sato T, Watanabe T, Nakagawa S, Otsuka N, Ohira H, Konno S. Pulmonary capillary hemangiomatosis-predominant vasculopathy in a patient with rheumatoid arthritis-associated interstitial lung disease: An autopsy report. Respir Med Case Rep 2020; 31:101215. [PMID: 33024689 PMCID: PMC7527749 DOI: 10.1016/j.rmcr.2020.101215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 09/03/2020] [Accepted: 09/03/2020] [Indexed: 11/23/2022] Open
Abstract
Pulmonary capillary hemangiomatosis (PCH) is a rare cause of pulmonary hypertension (PH) associated with poor prognosis. Clinically, it is characterized by severe hypoxemia, centrilobular ground-glass opacities on computed tomography, and pulmonary congestion triggered by pulmonary vasodilating therapy. In some cases, PCH has been reported to develop with other disorders including connective tissue disease; however, to date, no reports have described PCH in a patient with rheumatoid arthritis. We report a case of a 59-year-old male PCH patient with rheumatoid arthritis and associated pulmonary fibrosis. He was initially diagnosed with severe group 3 PH and received sildenafil, which generated a favorable hemodynamic response. However, 5 years later, his pulmonary hemodynamics deteriorated, and he died at the age of 67. An autopsy was performed, and thickening of alveolar septa and capillary proliferation, pathological features of PCH, were extensively observed in both lungs. We discuss when PCH developed, how sildenafil improved his hemodynamics, and how PCH could be clinically detected by noninvasive evaluations.
Collapse
Affiliation(s)
- Junichi Nakamura
- First Department of Medicine, Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo, 060-8648, Japan
| | - Ichizo Tsujino
- First Department of Medicine, Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo, 060-8648, Japan.,Department of Cardiology, KKR Sapporo Medical Center, 3-40 1-jo, 6-chome, Toyohira-ku, Sapporo, 062-0931, Japan
| | - Gaku Yamamoto
- First Department of Medicine, Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo, 060-8648, Japan
| | - Toshitaka Nakaya
- First Department of Medicine, Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo, 060-8648, Japan
| | - Kei Takahashi
- First Department of Medicine, Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo, 060-8648, Japan
| | - Hirokazu Kimura
- First Department of Medicine, Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo, 060-8648, Japan
| | - Takahiro Sato
- Department of Cardiology, KKR Sapporo Medical Center, 3-40 1-jo, 6-chome, Toyohira-ku, Sapporo, 062-0931, Japan
| | - Taku Watanabe
- First Department of Medicine, Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo, 060-8648, Japan
| | - Shimpei Nakagawa
- Department of Pathology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan
| | - Noriyuki Otsuka
- Department of Pathology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan
| | - Hiroshi Ohira
- First Department of Medicine, Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo, 060-8648, Japan
| | - Satoshi Konno
- First Department of Medicine, Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo, 060-8648, Japan
| |
Collapse
|